PI3K/mTOR | GSK2126458 (omipalisib) | Dose escalation studies in solid cancer (NCT00972686) and proof of mechanism trial in IPF (NCT01725139) |
mTORC1 | Everolimus | FDA-approved for pancreatic neuroendocrine tumours and advanced breast cancer |
| Sirolimus | Lymphangioleiomyomatosis (Phase I: NCT02432560) |
| | Organ rejection in kidney transplant (Phase I: NCT01236378; Phase II: NCT00076570) |
mTORC1/2 | AZD8055 | Recurrent gliomas, liver cancer and advanced tumours (Phase I: NCT01316809) |
| AZD2014 (vistusertib) | Glioblastoma multiforme (Phase I: NCT02619864, NCT03071874) |
| | Meningiomas (Phase II: NCT02831257) |
| | High-risk prostate cancer (Phase II: NCT02064608) |
| MLN0128 | Advanced solid tumours (Phase I: NCT02719691) |
| | Sarcoma (Phase I: NCT02987959) |